Reference : Pretreatment with P2Y12 inhibitors and outcome in patients with ST-segment elevation ...
Scientific journals : Article
Human health sciences : Cardiovascular & respiratory systems
http://hdl.handle.net/2268/225748
Pretreatment with P2Y12 inhibitors and outcome in patients with ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention
English
Gach, Olivier [Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques >]
Nyssen, Anne-Sophie [Université de Liège - ULiège > Département de Psychologie > Ergonomie et intervention au travail >]
GAYETOT, Christiane [Centre Hospitalier Universitaire de Liège - CHU > > Service de psychiatrie >]
Magne, J. [Centre Hospitalier Universitaire de Limoges, Service de Cardiologie, Limoges, France]
Oury, Cécile mailto [Université de Liège - ULiège > Département des sciences biomédicales et précliniques > GIGA-R : GIGA - Cardiovascular Sciences >]
Lancellotti, Patrizio [Université de Liège - ULiège > Département des sciences cliniques > Cardiologie - Pathologie spéciale et réhabilitation >]
2018
Journal of Cardiovascular Medicine
Lippincott Williams and Wilkins
19
5
234-239
Yes (verified by ORBi)
International
1558-2027
1558-2035
[en] Acute coronary syndrome ; Outcome ; P2Y12 inhibitors ; STsegment elevation myocardial infarction
[en] Aims Preload with clopidogrel, ticagrelor, or prasugrel in the setting of ST-segment elevation myocardial infarction (STEMI) treated by primary percutaneous coronary intervention (PCI) is frequently applied. Limited data are available regarding the outcome impact of pretreatment with these drugs in the real world. Methods and results The outcome of 760 STEMI patients treated by primary PCI receiving clopidogrel, prasugrel, or ticagrelor (nU269, 327, 164, respectively) was evaluated. Patients in the clopidogrel group were older, whereas those in the ticagrelor group had less hypertension but were more active smokers. Angiographic characteristics were comparable among the three groups. At 1 month, more events were observed in the clopidogrel group (11.1%) than in the ticagrelor and prasugrel groups (7.1 vs. 5.1%, P=0.025), whereas the number of events in the ticagrelor and prasugrel groups did not differ. At 1 year, similar differences existed, mainly driven by a higher rate of death (19.5%, P=0.008) or stent thrombosis (2 vs. 1.3% for ticagrelor, P=0.132; vs. 0.3% for prasugrel, P=0.07) in the clopidogrel group. In-hospital and 1-year bleeding rates were similar between groups. Conclusion In real-world practice, pretreatment with prasugrel or ticagrelor in ongoing STEMI treated by primary PCI seems to be a well tolerated alternative strategy compared with clopidogrel but provides superior benefit in terms of outcomes. © 2018 Italian Federation of Cardiology. All rights reserved.
http://hdl.handle.net/2268/225748
10.2459/JCM.0000000000000643

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
gach2018.pdfPublisher postprint123.29 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.